AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11273575
Drug: Natural work-life
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural work-life intervention allowing up to five days of self-administered sick leave with full financial compensation up to four times a year.
Trial: 26268104
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement with micronutrients and plant extracts
Trial: 21572981
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral ivermectin (200 microgram/kilogram body weight)
Trial: 21572981
Drug: Double doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double doses of oral ivermectin (given 2 weeks apart)
Trial: 21572981
Drug: 7-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day course of oral albendazole (800 mg daily)
Trial: 19880462
Drug: Second-generation antidepressants
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antidepressants (various types)
Trial: 19880462
Drug: Policies that
RxNorm normalized name: Polistes fuscatus whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policies that improve access to care (e.g., encouraging primary care treatment of depression)
Trial: 19880462
Drug: Policies that
RxNorm normalized name: Polistes fuscatus whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policies that promote treatment adherence (e.g., pay-for-performance initiatives)
Trial: 16214831
Drug: Ablation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablation and antiarrhythmic drug therapy
Trial: 16214831
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug therapy alone (control group)
Trial: 12525441
Drug: Flutamide (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (125 mg/day) + Metformin (1275 mg/day) + Low-dose Oral Contraceptive (ethinyl estradiol 20 microg + gestodene 75 microg)
Trial: 12525441
Drug: Flutamide (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (125 mg/day) + Metformin (1275 mg/day)
Trial: 6123806
Drug: Azathioprine and
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine and steroids (control)
Trial: 24774721
Drug: Hypofractionated carbon
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypofractionated carbon ion radiation therapy (64 GyE in 16 fractions)
Trial: 24774721
Drug: Hypofractionated proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated proton radiation therapy (64 GyE in 16 fractions)
Trial: 24774721
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (carbon ion and proton therapy)
Trial: 18928998
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (1000 mg or less intravenously over 15 minutes, repeated weekly to a maximum of 2500 mg)
Trial: 29858106
Drug: H.E.L.P.-apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H.E.L.P.-apheresis
Trial: 10687932
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (prednisolone, dextranes, pentoxifyllin)
Trial: 1925896
Drug: Estrogen receptor
RxNorm normalized name: Estrogen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen receptor positive (ER+) tumors (greater than or equal to 3 femtomoles per milligram cytosol of protein)
Trial: 1925896
Drug: Estrogen receptor
RxNorm normalized name: Estrogen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen receptor negative (ER-) tumors (less than 3 femtomoles per milligram cytosol protein)
Trial: 6918220
Drug: Mevinolin 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mevinolin 5 mg
Trial: 6918220
Drug: Mevinolin 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mevinolin 15 mg
Trial: 6918220
Drug: Mevinolin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mevinolin 50 mg
Trial: 30793994
Drug: Caffeine intervention:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine intervention: 216 mg caffeine from coffee beverages made from 6 g pure coffee beans (36 mg of caffeine per gram).
Trial: 30793994
Drug: Control: 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: 200 mg lactose without caffeine.
Trial: 23043923
Drug: Yiqiyangxin Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqiyangxin Chinese medicine compound combined with cognitive therapy
Trial: 23043923
Drug: Paroxetine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine combined with cognitive therapy
Trial: 18444446
Drug: Sufentanil +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil + Haloperidol 3 mg/h infusion
Trial: 18444446
Drug: Sufentanil +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil + Propofol 25 microg/kg/min infusion
Trial: 18444446
Drug: Sufentanil +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil + Midazolam 0.04 mg/kg/h infusion
Trial: 18444446
Drug: Sufentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil infusion (Control group)
Trial: 1681918
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g intravenously at the time of skin incision (Group I, n = 112)
Trial: 1681918
Drug: Cefuroxime 1.5
RxNorm normalized name: cefuroxime 1.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 1.5 g intravenously at the time of skin incision, followed by a second dose eight hours later (Group II, n = 107)
Trial: 6627831
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and Acetaminophen (concurrent use)
Trial: 27774917
Drug: High dietary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dietary calcium meal (HDCM; 547 mg DC)
Trial: 27774917
Drug: High supplemental
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High supplemental calcium meal (HSCM; 500 mg SC-calcium carbonate)
Trial: 27774917
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium meal (LCM; 42 mg DC)
Trial: 15613414
Drug: Testosterone patches
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone patches (300 mcg testosterone over 24 hours, applied twice weekly)
Trial: 9527734
Drug: Propofol 30
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 30 mg x h(‐1)
Trial: 9527734
Drug: Fat emulsion
RxNorm normalized name: FAT EMULSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat emulsion (Intralipid) 3 ml x h(‐1)
Trial: 1148032
Drug: Halofenate (MK-185,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofenate (MK-185, 1 g/day)
Trial: 24122944
Drug: MK-7288 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-7288 (10, 20 mg)
Trial: 18727657
Drug: SRP+MTZ+AMX (metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP+MTZ+AMX (metronidazole 400 mg 3 x per day and amoxicillin 500 mg 3 x per day for 14 days)
Trial: 18727657
Drug: SRP+MTZ (metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP+MTZ (metronidazole 400 mg 3 x per day for 14 days)
Trial: 14583903
Drug: Pharmacist-led intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led intervention (monthly consultations for 6 months)
Trial: 8765459
Drug: Topical Aloe
RxNorm normalized name: Alo Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Aloe vera extract 0.5% in a hydrophilic cream
Trial: 7933528
Drug: L-627 (biapenem)
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-627 (biapenem) at a dose of 10 mg/kg and 12 mg/kg
Trial: 28175295
Drug: Vernakalant (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vernakalant (3 mg/kg followed by 2 mg/kg if necessary)
Trial: 28175295
Drug: Ibutilide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide (1 mg followed by another 1 mg if necessary)
Trial: 27253482
Drug: 1000 IU
RxNorm normalized name: D 1000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU of vitamin D3 and 1500 mg of calcium daily; 50,000 IU of ergocalciferol (vitamin D2) weekly for vitamin D deficient and insufficient patients until levels normalized or fractures healed.
Trial: 19196106
Drug: Splinting plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Splinting plus low-level laser (LLL) therapy
Trial: 16946685
Drug: Oral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogen therapy (0.625 mg of conjugated equine estrogens per tablet)
Trial: 16946685
Drug: Topical estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical estrogen therapy (0.625 mg conjugated equine estrogens per 1 g vaginal cream)
Trial: 8842586
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 1 mg gemeprost every 6 hours (Group I)
Trial: 8842586
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 0.5 mg gemeprost every 6 hours (Group II)
Trial: 8842586
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received 5 x 1 mg gemeprost every 3 hours if abortion had not occurred after 24 hours
Trial: 8842586
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (0.5 mg)
Trial: 1519677
Drug: Tramadol (642
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (642 mg)
Trial: 1519677
Drug: Tramadol (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (0.5, 1.0, and 2.0 mg.kg‐1)
Trial: 1519677
Drug: Morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulphate (0.143 mg.kg‐1)
Trial: 29038236
Drug: Prochlorperazine 5
RxNorm normalized name: prochlorperazine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine 5 mg, given three times daily for 5 days
Trial: 29038236
Drug: Placebo, given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, given three times daily for 5 days
Trial: 26012345
Drug: Dexmedetomidine 0.38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.38 μg/kg
Trial: 19365139
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D dose decreased
Trial: 19365139
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D dose increased
Trial: 17515459
Drug: Reminder for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminder for use of beta-blockers
Trial: 15601388
Drug: Landiolol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol (0.1 mg/kg)
Trial: 9369918
Drug: Consolidating WBI
RxNorm normalized name: BAG,LEG LARGE CONSOLIDATED #0932
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidating WBI after systemic chemotherapy
Trial: 1245147
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g L-dopa
Trial: 1245147
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g L-dopa and 1.0 g L-tryptophan
Trial: 28222947
Drug: Stabilization splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilization splint therapy following arthrocentesis
Trial: 28222947
Drug: Splint therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Splint therapy only
Trial: 23507090
Drug: Self-reported prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported prescription filling
Trial: 11274308
Drug: Rapid initiation
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid initiation (900 mg/day immediately following the placebo lead-in)
Trial: 11274308
Drug: Slow initiation
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow initiation (300 mg day 1, 600 mg day 2, then 900 mg/day)
Trial: 9249101
Drug: E +
RxNorm normalized name: Perle +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E + D (Dopamine infusion during epidural anesthesia)
Trial: 7685682
Drug: diclofenac/misoprostol 50mg/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac/misoprostol 50mg/200 micrograms 2 or 3 times daily
Trial: 3323368
Drug: ICRC antileprosy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICRC antileprosy vaccine (0.5 x 10(9) or 1.7 x 10(7) bacilli, intradermally)
Trial: 19900209
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with OloGen implant
Trial: 19900209
Drug: Trabeculectomy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trabeculectomy without OloGen implant (control group)
Trial: 18559917
Drug: AG infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AG infusion
Trial: 18559917
Drug: Naloxone (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.1 mg/kg iv as a slow bolus)
Trial: 10608295
Drug: Colostrinin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colostrinin (100 microg per tablet, every second day)
Trial: 10608295
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available bioorganic selenium (100 microg selenium per tablet, every second day)
Trial: 7477801
Drug: Combined cognitive‐behavioral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cognitive‐behavioral, nutritional and antidepressant therapy (7 with amineptine and 6 with fluoxetine)
Trial: 1951111
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (15, 30, 45, 60, 75, 90, and 105 mg/24 hours)
Trial: 1951111
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (various doses)
Trial: 1951111
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (highest dose)
Trial: 7028786
Drug: PGI2 infusion
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGI2 infusion at 0.1 ng/kg per min
Trial: 7028786
Drug: PGI2 infusion
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGI2 infusion at 0.4 ng/kg per min
Trial: 7028786
Drug: PGI2 infusion
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGI2 infusion at 2.0 ng/kg per min
Trial: 7028786
Drug: Control (vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (vehicle infusion)
Trial: 7028786
Drug: Exogenous PGI2
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exogenous PGI2 infusion rates
Trial: 12959951
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg slow-release caffeine (SRC) from recovery day 1 (D1) to D5 (0800)
Trial: 12959951
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg melatonin (Mlt) on preflight D-1 (1700), flight day D0 (1600), and from D1 to D3 (2300)
Trial: 12166613
Drug: Nimesulide (2.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (2.9 mg/kg)
Trial: 12166613
Drug: Diclofenac (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (3.0 mg/kg)
Trial: 12166613
Drug: Celecoxib (12.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (12.7 mg/kg)
Trial: 12166613
Drug: Rofecoxib (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (3.0 mg/kg)
Trial: 12166613
Drug: All drugs
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drugs (Nimesulide, Diclofenac, Celecoxib, Rofecoxib)
Trial: 7865386
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with cyclophosphamide and low-dose corticosteroids
Trial: 2744314
Drug: Mexiletine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (200 mg q.i.d.)
Trial: 194524
Drug: Antibiotic-corticosteroid solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-corticosteroid solution
Trial: 194524
Drug: Antibiotic-corticosteroid suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-corticosteroid suspension
Trial: 25954025
Drug: Violet syrup
RxNorm normalized name: acid violet 43
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Violet syrup
Trial: 21425885
Drug: Oral indomethacin/prochlorperazine/caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral indomethacin/prochlorperazine/caffeine
Trial: 21425885
Drug: Rectal indomethacin/prochlorperazine/caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal indomethacin/prochlorperazine/caffeine
Trial: 17490753
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) group intervention
Trial: 1460211
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (IB) nasal spray (84 micrograms/nostril, two sprays per nostril, four times a day for 4 days)
Trial: 1460211
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (IB) nasal spray
Trial: 6419709
Drug: XYY men
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XYY men with higher concentrations of testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH)
Trial: 31158087
Drug: Docetaxel (75mg/m2)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (75mg/m2) administered alongside standard of care (SOC) hormone therapy for ≥2 years and radiotherapy in some patients.
Trial: 31158087
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) hormone therapy for ≥2 years and radiotherapy in some patients.
Trial: 22658231
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic (group L)
Trial: 15852407
Drug: Once-daily radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily radiotherapy (QDRT)
Trial: 15852407
Drug: Twice-daily radiotherapy
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily radiotherapy (BIDRT)
Trial: 12774967
Drug: Aspirin 25
RxNorm normalized name: aspirin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 25 mg/kg PO q8h
Trial: 8420491
Drug: Oral azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azathioprine (100 to 150 mg/d) in combination with oral prednisolone (1 mg/kg per day)
Trial: 8420491
Drug: Four large-volume
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four large-volume plasma exchanges in combination with oral prednisolone (1 mg/kg per day)
Trial: 8420491
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (1 mg/kg per day) alone
Trial: 3541816
Drug: Milacemide 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milacemide 400 mg b.i.d. (week 1)
Trial: 3541816
Drug: Milacemide 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milacemide 1,200 mg b.i.d. (week 2)
Trial: 3541816
Drug: Milacemide 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milacemide 400 mg (superimposed dosage on day 8)
Trial: 3541816
Drug: Milacemide 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milacemide 1,200 mg (superimposed dosage on day 15)
Trial: 3541816
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment (1 week and 2 weeks)
Trial: 22731754
Drug: 500/100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500/100 μg fluticasone/salmeterol Diskus daily
Trial: 22731754
Drug: 400/24 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/24 μg extrafine beclomethasone/formoterol pMDI daily
Trial: 20092966
Drug: modafinil (400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modafinil (400mg once daily)
Trial: 20092966
Drug: placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (once daily)